Compared efficacy of rituximab, abatacept, and tocilizumab in patients with rheumatoid arthritis refractory to methotrexate or TNF inhibitors agents: a systematic review and network meta-analysis.
Alisson PugliesiAmanda Borges de OliveiraAna Beatrice OliveiraRicardo Machado XavierLicia Maria Henrique da MotaManoel Barros BertoloMiguel Angel González-GayGustavo CiteraLuiz Sérgio Fernandes de CarvalhoPublished in: Advances in rheumatology (London, England) (2023)
We found high heterogeneity among studies comparing rituximab, abatacept, and tocilizumab. On multivariate metaregressions, if the conditions of the RCTs were similar, we estimate that abatacept could increase the chance of reaching an ACR70 response by 2.2-fold compared to tocilizumab.